Table 3.
Cox regression analyses by HER2 status in 458 women with a primary DCIS
| DCIS | ||
|---|---|---|
| HER2 positive | HER2 negative | |
| HR (95 % CI) | HR (95 % CI) | |
| Ipsilateral Breast Events (IBE) | ||
| BCS (n = 331) (events = 95) | ||
| Univariate HR (95 % CI) | 1.20 (0.78–1.85) | (Ref) |
| aAdjusted HR (95 % CI) | 1.27 (0.83–1.96) | (Ref) |
| bAdjusted HR (95 % CI) | 1.17 (0.75–1.83) | (Ref) |
| cAdjusted HR (95 % CI) | 1.22 (0.76–1.95) | (Ref) |
| BCS, in situ IBEs (events = 49) | ||
| Univariate HR (95 % CI) | 1.63 (0.92–2.89) | (Ref) |
| aAdjusted HR (95 % CI) | 1.76 (0.99–3.11) | (Ref) |
| bAdjusted HR (95 % CI) | 1.40 (0.77–2.54) | (Ref) |
| cAdjusted HR (95 % CI) | 1.65 (0.88–3.11) | (Ref) |
| BCS, invasive IBEs (events = 46) | ||
| Univariate HR (95 % CI) | 0.78 (0.40–1.55) | (Ref) |
| aAdjusted HR (95 % CI) | 0.83 (0.42–1.64) | (Ref) |
| bAdjusted HR (95 % CI) | 0.87 (0.43–1.75) | (Ref) |
| cAdjusted HR (95 % CI) | 0.80 (0.38–1.66) | (Ref) |
| Invasive Breast Cancer Recurrence (IBCR) | ||
| All patients (n = 420) (Events = 102) | ||
| Univariate HR (95 % CI) | 0.60 (0.38–0.94) | (Ref) |
| aAdjusted HR (95 % CI) | 0.58 (0.38–0.95) | (Ref) |
| bAdjusted HR (95 % CI) | 0.59 (0.37–0.95) | (Ref) |
| cAdjusted HR (95 % CI) | 0.59 (0.36–0.98) | (Ref) |
BCS breast conserving surgery
aAdjusted for radiotherapy
bAdjusted for radiotherapy, age at diagnosis (continuous) and size
cAdjusted for radiotherapy, age at diagnosis and ER